Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer
- 551 Downloads
Several genomic regions are frequently altered and associated with the type, stage and progression of urinary bladder cancer (UBC). We present the characterization of 5637, T24 and HT1376 UBC cell lines by karyotyping, fluorescence in situ hybridization (FISH), array comparative genomic hybridization (aCGH) and multiplex ligation-dependent probe amplification (MLPA) analysis. Some cytogenetic anomalies present in UBC were found in the three cell lines, such as chromosome 20 aneuploidy and the loss of 9p21. Some gene loci losses (e.g. CDKN2A) and gains (e.g. HRAS, BCL2L1 and PTPN1) were coincident across all cell lines. Although some significant heterogeneity and complexity were detected between them, their genomic profiles exhibited a similar pattern to UBC. We suggest that 5637 and HT1376 represent the E2F3/RB1 pathway due to amplification of 6p22.3, concomitant with loss of one copy of RB1 and mutation of the remaining copy. The HT1376 presented a 10q deletion involving PTEN region and no alteration of PIK3CA region which, in combination with the inactivation of TP53, bears more invasive and metastatic properties than 5637. The T24 belongs to the alternative pathway of FGFR3/CCND1 by presenting mutated HRAS and over-represented CCND1. These cell lines cover the more frequent subtypes of UBC and are reliable models that can be used, as a group, in preclinical studies.
KeywordsUrinary bladder cancer Urinary bladder cancer cell lines Genomic Chromosome aCGH MLPA
The authors express their deepest appreciation to Célia Carvalho of the Instituto de Medicina Molecular, Lisboa, Portugal, for review of the manuscript.
Conflicts of interest
- 3.Escudero D, Shirodkar S, Lokeshwar V. Bladder carcinogenesis and molecular pathways. In: Lokeshwar VB, Merseburger AS, Hautmann SH, editors. Bladder tumours: molecular aspects and clinical management. Totowa: Humana; 2011. p. 29–32.Google Scholar
- 12.Gallucci M, Guadagni F, Marzano R, Leonardo C, Merola R, Sentinelli S. Status of the p53, p16, RB1, and HER-2 genes and chromosomes 3, 7, 9, and 17 in advanced bladder cancer: correlation with adjacent mucosa and pathological parameters. J Clin Pathol. 2005;58(4):367–71.CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Karkoulis PK, Stravopodis DJ, Konstantakou EG, Voutsinas GE. Targeted inhibition of heat shock protein 90 disrupts multiple oncogenic signaling pathways, thus inducing cell cycle arrest and programmed cell death in human urinary bladder-cancer cell lines. Cancer Cell Int. 2013;13(1):11.CrossRefPubMedPubMedCentralGoogle Scholar
- 26.Shaffer LG, Slovak ML, Campbell LJ. ISCN: an International System for Human Cytogenetic Nomenclature: recommendations of the International Standing Committee on Human Cytogenetic Nomenclature. S. Karger. 2009.Google Scholar
- 30.DSMZ. German collection of microorganisms and cell cultures. http://www.dsmz.de
- 42.Mitelman F, Johansson B, Mertens F. Mitelman database of chromosome aberrations in cancer. http://cgap.nci.nih.gov/Chromosomes/Mitelman. 2008; Accessed 25 January 2013.
- 54.Safran M, Dalah I, Alexander J, Rosen N, Iny Stein T, Shmoish M, et al. GeneCards version 3: the human gene integrator. Database (Oxford). 2010;2010:baq020.Google Scholar